Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)
Keros Therapeutics posted quarterly Income from Continuing Operations of 23461000.0 for Q4 2025, up 49.03% year-on-year from 15742823.2 in Q4 2024, and down 222.27% on a QoQ basis from 7280000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Income from Continuing Operations data on file, last reported at 23461000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 49.03% year-over-year to 23461000.0; the trailing twelve-month figure through Dec 2025 stood at 87014000.0 (up 146.44% YoY), and the FY2025 full-year result was 87014000.0, up 146.44% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 23461000.0, down from 7280000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 148451000.0 in Q1 2025 and bottomed at 52956000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 28492000.0 (2022), against an average of 21685150.0.
- The widest annual swing landed in 2022, when Income from Continuing Operations slumped 328.21%; it then jumped 444.32% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6940000.0 in 2021, then plunged by 328.21% to 29718000.0 in 2022, then tumbled by 56.32% to 46455000.0 in 2023, then rose by 0.92% to 46026000.0 in 2024, then jumped by 49.03% to 23461000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 23461000.0 (Q4 2025), 7280000.0 (Q3 2025), and 30696000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -23.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -43.28 Mn |
| Jun 30, 2023 | -41.34 Mn |
| Mar 31, 2023 | -38.87 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |
| Mar 31, 2021 | -15.89 Mn |
| Dec 31, 2020 | -10.68 Mn |
| Sep 30, 2020 | -12.04 Mn |
| Jun 30, 2020 | -10.76 Mn |
| Mar 31, 2020 | -11.89 Mn |
| Dec 31, 2019 | -2.75 Mn |
| Sep 30, 2019 | -3.55 Mn |
| Jun 30, 2019 | -2.85 Mn |
| Mar 31, 2019 | -3.18 Mn |